However, several tests like the cobas EGFR Mutation Test 2 (Roche) that detect EGFR mutations in Non-Small Cell Lung Cancer (NSCLC), the Epi pro Colon (Epigenomics AG) for colorectal cancer patients,4 the Guardant 360 CDx comprehensive genomic profiling (CGP) for the simultaneous assessment of single nucleotide variations (SNVs) or insertion and deletions in 55 tumor-associated genes5 and the 324 gene F1 Liquid CDx for use in (NSCLC) or prostate cancer meet all three criteria.6 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.